Munich Reinsurance Co Stock Corp in Munich Invests $63.51 Million in Elevance Health, Inc. $ELV

Munich Reinsurance Co Stock Corp in Munich bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 196,537 shares of the company’s stock, valued at approximately $63,505,000. Elevance Health makes up 1.6% of Munich Reinsurance Co Stock Corp in Munich’s investment portfolio, making the stock its 20th largest holding. Munich Reinsurance Co Stock Corp in Munich owned about 0.09% of Elevance Health at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vermillion & White Wealth Management Group LLC lifted its position in shares of Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new stake in Elevance Health in the 2nd quarter worth approximately $32,000. Physician Wealth Advisors Inc. raised its stake in Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the period. Rossby Financial LCC raised its stake in Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the period. Finally, Activest Wealth Management lifted its holdings in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ELV shares. Mizuho set a $413.00 price target on shares of Elevance Health in a research report on Friday, January 9th. Leerink Partners lifted their target price on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research note on Thursday, January 29th. Robert W. Baird upped their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Jefferies Financial Group cut their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Finally, Royal Bank Of Canada lowered Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research note on Tuesday, February 3rd. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Stock Up 1.1%

Shares of ELV stock opened at $289.56 on Friday. The company’s fifty day simple moving average is $344.64 and its two-hundred day simple moving average is $335.01. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The stock has a market cap of $63.91 billion, a P/E ratio of 11.53, a PEG ratio of 1.58 and a beta of 0.51. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter last year, the business posted $3.84 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.